Oncothyreon, Inc. (NASDAQ:ONTY)

CAPS Rating: 4 out of 5

Results 1 - 13 of 13

Recs

0
Member Avatar Haugurafpeningum (28.59) Submitted: 2/27/2015 11:06:23 AM : Outperform Start Price: $1.70 ONTY Score: -4.98

David Nierengarten target $4

Recs

0
Member Avatar Amoeba17 (63.40) Submitted: 12/17/2014 2:17:47 PM : Outperform Start Price: $1.79 ONTY Score: -14.70

With a few of their products performing decently in clinical trials, I think this company is going to get scooped up by a larger company. I'm betting on that happening in the next year or two.

Recs

0
Member Avatar Tophinater (45.21) Submitted: 11/4/2014 2:51:34 PM : Underperform Start Price: $1.77 ONTY Score: +13.84

yep.

Recs

0
Member Avatar whoodatstockhot (86.53) Submitted: 9/25/2013 12:00:39 PM : Outperform Start Price: $2.28 ONTY Score: -53.70

Strong probability tecemotide succeeds in stage 3 trial-- which would push shares above the $4 dollar mark. Also, nice chance of Merck buyout before then, which would provide significant upside. Potential homerun in the making here.

Recs

0
Member Avatar fatmoneyrz (99.18) Submitted: 9/25/2013 9:52:01 AM : Outperform Start Price: $2.24 ONTY Score: -52.97

Big upside with START2. $3+ valuation in near-term.

Recs

0
Member Avatar stainsolution (67.16) Submitted: 4/4/2012 8:53:38 PM : Outperform Start Price: $4.20 ONTY Score: -113.52

Cancer Bio. Hammered recently. Willing to buy here/ hold for the Ph III run up.

Recs

0
Member Avatar RBuskey106 (57.98) Submitted: 3/14/2012 10:46:05 PM : Outperform Start Price: $4.84 ONTY Score: -117.82

Waiting for Ph 3 stimuvax results...thinking stock may have bottomed.

Recs

1
Member Avatar ccatania13 (< 20) Submitted: 11/21/2011 12:17:13 AM : Outperform Start Price: $7.08 ONTY Score: -153.48

Another stock getting ready to break out. This stock is undervalued right now, and it is prime for the picking. Get ready for shooting star.

Recs

2
Member Avatar siliconvalleyboy (< 20) Submitted: 5/23/2011 1:46:14 AM : Outperform Start Price: $5.56 ONTY Score: -131.49

Very compelling early data from phase II. Existing trial is continuing and data is expected late Q2. Very strong pipeline ahead of them. 1 small molecule with very good chemistry AND a more powerful version of the existing drug, this new drug is not partnered and its value will go up tremendously with the approval, if and when it happens.

Recs

0
Member Avatar RSorak (< 20) Submitted: 4/7/2011 10:12:01 AM : Outperform Start Price: $5.53 ONTY Score: -155.48

See slide 15 of yesterdays Needham conf. Absolutely amazing results.....Zero cancer growth.

Recs

0
Member Avatar Stonesolidpicks (< 20) Submitted: 12/4/2009 5:53:37 PM : Outperform Start Price: $4.84 ONTY Score: -157.67

Cancer drug in Phase 3

Recs

0
Member Avatar mbs9 (< 20) Submitted: 8/27/2009 10:34:35 PM : Outperform Start Price: $5.57 ONTY Score: -175.27

it has some "hidden" gems ready to be announced

Recs

0
Member Avatar TMFBiologyFool (96.68) Submitted: 8/3/2009 2:37:24 PM : Outperform Start Price: $5.65 ONTY Score: -184.79

Promising drugs don't deserve $100 million market caps.

Results 1 - 13 of 13

Featured Broker Partners


Advertisement